Mr Alastair Mobley BSc MRes

Mr Alastair Mobley

Department of Cardiovascular Sciences
Trial Team Manager

Contact details

Address
Floor 2, Institute of Translational Medicine
Heritage Building
Mindelsohn Way
Birmingham
B15 2TH

Alastair is a Trial Team Manager and PhD Student based at the Department of Cardiovascular Science. With nearly 10 years of experience in delivering clinical trial in both cardiology and Primary Care, he has managed a broad portfolio of clinical trials including the first national data enabled clinical trial, DaRe2THINK. His work in healthcare data enabled clinical trials continues as a co-applicant on the Horizon Europe HYPERMARKER clinical trial and work with the West Midlands NHS Subnational Secure Data Environment.

Alastair’s Academic work focuses on the mechanisms linking Atrial Fibrillation, Vascular Disease, and Vascular Dementia

Qualifications

  • MRes Biomedical Research, University of Birmingham, 2015
  • BSc Medical Biochemistry, Swansea University, 2014

Other activities

Publications

Recent publications

Article

Zhang, Y, Liu, B, Bunting, KV, Brind, D, Thorley, A, Karwath, A, Lu, W, Zhou, D, Wang, X, Mobley, AR, Tica, O, Gkoutos, GV, Kotecha, D & Duan, J 2024, 'Development of automated neural network prediction for echocardiographic left ventricular ejection fraction', Frontiers in Medicine, vol. 11, 1354070. https://doi.org/10.3389/fmed.2024.1354070

Champsi, A, Mobley, A, Subramanian, A, Nirantharakumar, K, Wang, X, Shukla, D, Bunting, K, Molgaard, I, Dwight, J, Casado Arroyo, R, Crijns, HJGM, Guasti, L, Lettino, M, Lumbers, RT, Maesen, B, Rienstra, M, Svennberg, E, Tica, O, Traykov, V, Tzeis, S, van Gelder, I & Kotecha, D 2024, 'Gender and contemporary risk of adverse events in atrial fibrillation', European Heart Journal, vol. 45, no. 36, ehae539. https://doi.org/10.1093/eurheartj/ehae539

Mobley, AR, Subramanian, A, Champsi, A, Wang, X, Myles, P, McGreavy, P, Bunting, KV, Shukla, D, Nirantharakumar, K & Kotecha, D 2024, 'Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk', Nature Medicine. https://doi.org/10.1038/s41591-024-03049-9

Wang, X, Mobley, A, Tica, O, Okoth, K, Nirantharakumar, K, Shukla, D & Kotecha, D 2022, 'Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomised trial', European Heart Journal, vol. 3, no. 3, ztac046, pp. 426-436. https://doi.org/10.1093/ehjdh/ztac046

Karwath, A, Bunting, KV, Gill, SK, Tica, O, Pendleton, S, Aziz, F, Barsky, AD, Chernbumroong, S, Duan, J, Mobley, AR, Cardoso, VR, Slater, L, Williams, JA, Bruce, E, Wang, X, Flather, MD, Coats, AJS, Gkoutos, GV & Kotecha, D 2021, 'Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis', The Lancet, vol. 2021, no. 10309, pp. 1-9. https://doi.org/10.1016/s0140-6736(21)01638-x

Abstract

Mobley, A, Wang, X, Champsi, A, Subramanian, A, Nirantharakumar, K & Kotecha, D 2023, '90 Thromboembolic events and vascular dementia in contemporary patients with atrial fibrillation and low apparent stroke risk', Heart, vol. 109, no. Suppl 3, pp. A99-A101. https://doi.org/10.1136/heartjnl-2023-bcs.90